General Orthopaedics
Zoledronic acid improves health-related quality of life in patients with hip fractures
This report has been verified
by one or more authors of the
original publication.
Osteoporos Int. 2011 Sep;22(9):2539-49. doi: 10.1007/s00198-010-1514-9. Epub 2011 Jan 20
2,127 patients were randomized to assess the benefits of zoledronic acid (ZOL) on health-related quality of life among patients from The Health Outcomes and Reduced Incidence With Zoledronic Acid One Yearly Recurrent Fracture Trial (HORIZON-RFT). Patients received annual infusion of either ZOL 5 mg or placebo within 90 days following surgical repair of low-trauma hip fracture. The end of the study evaluation (up to 36 months) revealed that ZOL significantly improved health related quality of life among patients with low-trauma hip fractures.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
